

---

## **Section 172 Companies Act 2006 Statement**

The Company's governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the ViiV's long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company's other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

The Company has engaged with its main stakeholder groups, including our patients, shareholders, consumers, customers and Group employees, as further detailed in the stakeholder engagement statements in the Directors' Report and the feedback from the engagement has been considered by the Directors during the decision-making process.

Matters identified that may affect the Company's performance in the long term are set out in the principal risks disclosed above

## **ViiV Healthcare Limited**

---

## **Section 172 Companies Act 2006 Statement**

The Company's governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the Company's long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company's other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

The Company has engaged with its main stakeholder groups, including our patients, shareholders, consumers, customers and Group employees, as further detailed in the stakeholder engagement statements in the Directors' Report and the feedback from the engagement has been considered by the Directors during the decision-making process.

**Glaxo Operations UK Limited**

**GlaxoSmithKline UK Limited**

**GlaxoSmithKline Research & Development Limited**

**ViiV Healthcare Trading Services UK Limited**

**GlaxoSmithKline Intellectual Property Limited**

**GlaxoSmithKline Intellectual Property (No.2) Limited**

**GlaxoSmithKline Export Limited**

**GlaxoSmithKline Consumer Trading Services Limited**

**GlaxoSmithKline Services Unlimited**

**GlaxoSmithKline Consumer Healthcare (Overseas) Limited**

**Dealcyber Limited**

**Glaxo Group Limited**

**GlaxoSmithKline Caribbean Limited**

**GlaxoSmithKline Consumer Healthcare (UK) Trading Limited**

**ViiV Healthcare UK Limited**

**ViiV Healthcare UK (No.3) Limited**

**GlaxoSmithKline UK Limited**

**GlaxoSmithKline Mercury Limited**

**GlaxoSmithKline Holdings (Ireland) Limited**

**SmithKline Beecham Research Limited**

---

## **Section 172 Companies Act 2006 Statement**

The Company's governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the Company's long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company's other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

The Company has engaged with its main stakeholder groups, including our patients, shareholders, consumers, customers and Group employees, as further detailed in the stakeholder engagement statements in the Directors' Report and the feedback from the engagement has been considered by the Directors during the decision-making process.

Matters identified that may affect the Company's performance in the long term are set out in the principal risks disclosed above.

**GlaxoSmithKline Consumer Healthcare Finance No.2 Limited**  
**GlaxoSmithKline Consumer Healthcare Holdings (No.2) Limited**  
**GlaxoSmithKline Consumer Healthcare Sri Lanka Holdings Limited**  
**PRISM PCH Limited**

---

**Section 172 Companies Act 2006 Statement**

The Company's governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the TESARO UK Limited's long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company's other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

The Company has engaged with its main stakeholder groups, as further detailed in the stakeholder engagement statements in the Directors' Report and the feedback from the engagement has been considered by the Directors during the decision-making process.

Matters identified that may affect the Company's performance in the long term are set out in the principal risks disclosed above.

**Tesaro UK Limited**

---

**Section 172 Companies Act 2006 Statement**

The Company's governance architecture and processes are operated to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the Company's long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company's other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

**GlaxoSmithKline Consumer Healthcare (UK) IP Limited**

**PHIVCO UK II Limited**

**BEECHAM GROUP P L C**

**Galvani Bioelectronics Limited**

**Wellcome Limited**

**ViiV Healthcare Overseas Limited**

**Stiefel Consumer Healthcare (UK) Limited**

**SmithKline Beecham Overseas Limited**

**SmithKline Beecham Limited**

**SmithKline Beecham (H) Limited**

**PHIVCO UK II Limited**

**Horlicks Limited**

**GlaxoSmithKline Consumer Healthcare Holdings Limited**

**GlaxoSmithKline Holdings (One) Limited**

**GlaxoSmithKline Holdings Limited**

**GlaxoSmithKline Intellectual Property Development Limited**

**GlaxoSmithKline Intellectual Property Holdings Limited**

**GlaxoSmithKline Intellectual Property Management Limited**

---

**Section 172 Companies Act 2006 Statement**

The Company's governance architecture and processes operate to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the Company's long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the company's other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

Matters identified that may affect the Company's performance in the long term are set out in the principal risks disclosed both above and in the Group's 2019 Annual Report.

**GlaxoSmithKline Finance plc**  
**ViiV Healthcare Finance 2 Limited**  
**Setfirst Limited**  
**GlaxoSmithKline Investment Services Limited**  
**GlaxoSmithKline Investment Holdings Limited**  
**GlaxoSmithKline International Limited**  
**GlaxoSmithKline Consumer Healthcare Finance Limited**  
**GlaxoSmithKline IHC Limited**  
**GSK Finance (No 2) Limited**  
**GlaxoSmithKline Capital plc**  
**Glaxochem (UK) Unlimited**

---

**Section 172 Companies Act 2006 Statement**

The Company's governance architecture and processes operate to ensure that all relevant matters are considered by the Board in its principal decision-making, as a means of contributing to the delivery of the Company's long-term priorities of Innovation, Performance and Trust.

In the performance of its duty to promote the success of the Company and the long-term priorities, the Board has agreed to a number of matters, including listening to and considering the views of shareholders and the Company's other stakeholders to build trust and ensure it fully understands the potential impacts of the decisions it makes for our stakeholders, the environment and the communities in which we operate.

The Company has engaged with its main stakeholder groups, including our patients, shareholders, consumers, customers and Group employees, as further detailed in the stakeholder engagement statements in the Directors' Report and the feedback from the engagement has been considered by the Directors during the decision-making process. Matters identified that may affect the Company's performance in the long term are set out in the principal risks disclosed above.

**Consumer Healthcare Holdings Limited**

**Consumer Healthcare Intermediate Holdings Limited**